Comparative Pharmacology
Head-to-head clinical analysis: CHLOROPTIC P S O P versus TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROPTIC P S O P versus TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE.
CHLOROPTIC-P S.O.P. vs TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloroptic-P S.O.P. contains prednisolone acetate and chloramphenicol. Prednisolone acetate is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis. Chloramphenicol is a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate synthesis and thereby inhibiting thymidine synthesis. Polymyxin B disrupts bacterial cell membrane integrity by binding to lipopolysaccharides in Gram-negative bacteria.
Adults: Instill 1/2-inch ribbon into conjunctival sac 3-4 times daily, or more frequently as needed. Not for injection.
One drop in each affected eye every 2 to 4 hours for 7 to 10 days.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (systemic); prolonged to 21-24 hours in severe hepatic impairment. Clinical context: short half-life supports 2-3 times daily dosing.
Trimethoprim: 8-10 hours (normal renal function); Polymyxin B: 6 hours (prolonged in renal impairment).
Renal: 50-70% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites; small amount via lacrimal drainage after ophthalmic administration.
Trimethoprim: renal (80-90% unchanged, 10-20% metabolites); Polymyxin B: renal (60% unchanged, 40% nonrenal).
Category C
Category D/X
Antibiotic
Antibiotic